Replies to post #10654 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

There is a Dr Michael Werner who works at AbbVie. The timing of his work history is consistent with discovering the Breast Cancer event reduction in Libigel.

His work history:
AbbVie-
Asst. Scientific Director - Hematology/Oncology US Medical Affairs
Dec 2016 – Present (3 years 5 months)

Mettawa, IL

Medical Science Liaison - Oncology
Jan 2015 – Dec 2016 (2 years)

Chicago & Great Lakes


Teva Pharmaceuticals
Medical Science Liaison - Oncology
Oct 2012 – Jan 2015 (2 years 4 months)


Work history

October 4, 2012 is when BPAX announced the merger with ANIP. Teva sold ANIP its first basket of drugs after the merger.

Though this is not the same Dr Werner, I wonder if they might be related. The breast cancer discovery first surfaced in the patent prosecution December 19, 2015. The safety study, if completed, would have ended August 2016. Dr. Werner's work history lines up well with continuing the Libigel trial. Dr Werner is likely partially responsible for the breast cancer event reduction supporting data which is missing from the patent application.

[rgshredder]

Seriously fantastic find!
I'd say reach out to Dr. Werner too but that may be bordering harassment.

My only pessimistic view would be it remains in the "present" status only bc the study hasn't formally concluded or a paper is pending etc. Remember it's a CV so it'll be pretty loose with interpretation and written to favor him personally- more open studies equates to more collaborations/networking/contribution for someone seeking his talent.

I still think it's fantastic sleuthing and my optimistic side is breathing a sigh of relief.

-RG

[big bambino]

JTFM: Fantastic find!